Implantable Vagus Nerve Stimulator Reduces Rheumatoid Arthritis Activity in Pivotal RESET-RA Trial, Published in Nature Medicine
View StudyPlain-Language Summary
A pivotal clinical trial published in Nature Medicine in January 2026 found that an implantable vagus nerve stimulation device significantly reduced rheumatoid arthritis activity in patients who had failed multiple prior biological or targeted therapies. In the RESET-RA study, 35.2% of patients receiving active stimulation achieved the ACR20 response threshold at 3 months, compared to 24.2% in the sham control group, and response rates continued to improve to over 50% by 12 months of open-label treatment. The FDA has approved the SetPoint System based on these results, making it the first neuroimmune modulation device cleared for rheumatoid arthritis.
Abstract
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by synovial inflammation, joint destruction, and systemic inflammation driven by cytokines including TNF, IL-6, and IL-1. While biological disease-modifying antirheumatic drugs (bDMARDs) and JAK inhibitors have substantially improved outcomes, a meaningful proportion of patients have an inadequate response or intolerance to multiple agents and remain in persistent high disease activity. The cholinergic anti-inflammatory pathway, activated through vagus nerve stimulation, has emerged as a potential mechanism to reduce systemic cytokine production without the immune suppression associated with conventional therapies.
RESET-RA was a pivotal, double-blind, randomized, sham-controlled multicenter trial evaluating the SetPoint System, an implantable vagus nerve-targeted neuroimmune modulation device, in 242 adults with moderate-to-severely active RA who had an inadequate response or intolerance to at least one biological DMARD or JAK inhibitor. Participants were randomized to receive active vagus nerve stimulation or sham stimulation, with the primary endpoint being ACR20 response at 3 months.
ACR20 response at 3 months was achieved by 35.2% of patients in the active stimulation group compared to 24.2% in the sham group (p=0.0209). In the subsequent open-label phase, ACR20 rates continued to improve, reaching 50.0% at 6 months and 52.8% at 12 months. At 12 months, 77.3% of patients achieved a EULAR good or moderate response, 49.3% attained DAS28-CRP low disease activity or remission, and 75.2% remained free of any added biological DMARD or JAK inhibitor. A prespecified MRI subgroup analysis showed a 50% relative reduction in erosion progression in the treatment group compared to the sham group (p=0.016). Adverse event rates were comparable between groups. These results supported FDA approval of the SetPoint System as the first device-based neuroimmune modulation therapy for RA.